B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Agenus (AGEN) on January 8 and set a price target of $8.00. The company’s shares closed last Thursday at $3.42.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 34.3% and a 59.1% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
Agenus has an analyst consensus of Moderate Buy, with a price target consensus of $8.00.
See today’s analyst top recommended stocks >>
Based on Agenus’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $14.83 million and GAAP net loss of $51.15 million. In comparison, last year the company earned revenue of $19.94 million and had a GAAP net loss of $45.47 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
